Before the headlines, a bit of background to the presentation at a recent European meeting
GLP-1 agonists pose emerging challenge for PET-CT imaging, study finds | EurekAlert! GLP-1 agonists pose emerging challenge for PET-CT imaging, study finds | EurekAlert!
âŚand now for just one example of what most folk are going to read (and form opinions on)
New âunusualâ side effect of weight-loss drugs becoming more common, research suggests | The Independent New âunusualâ side effect of weight-loss drugs becoming more common, research suggests | The Independent
PET-CT scans are highly indicative, but low specificity. This is an interesting wrinkle that would be quite expensive to carriers, patients - and therapists!
I hope the radiology community gets this straightened out - and soon.
Well, I suspect the radiology community has been increasingly aware for a whileâŚ.even the presentation iteslf has this case report in its reference listâŚ
FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue - PubMed FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue - PubMed
âŚ.not that youâd expect these health and science writers to look beyond what can be gussied up into another âBewareâŚ.here be side effectsâ tale of danger.
The Independantâs headline is, as usual, misleading in its use of the term âside effectâ rather than a phenomenon that might be expected, given the way these drugs work to increase glucose uptake. Iâm willing to bet this wouldnât be the first time that patient medication (any medication) has been shown to confound the expected results of a test.